company background image
6881

Shandong Kexing Bioproducts Co.Ltd SHSE:688136 Stock Report

Last Price

CN¥20.09

Market Cap

CN¥4.0b

7D

-9.2%

1Y

-34.4%

Updated

23 Sep, 2022

Data

Company Financials
688136 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends1/6

688136 Stock Overview

Kexing Biopharmaceutical Co., Ltd., a biopharmaceutical enterprise, engages in the research and development, production, and sale of recombinant protein therapeutics and microbiota agents.

Shandong Kexing Bioproducts Co,.Ltd Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Shandong Kexing Bioproducts Co.Ltd
Historical stock prices
Current Share PriceCN¥20.09
52 Week HighCN¥38.00
52 Week LowCN¥20.06
Beta0
1 Month Change-17.80%
3 Month Change-27.86%
1 Year Change-34.37%
3 Year Changen/a
5 Year Changen/a
Change since IPO-51.01%

Recent News & Updates

Shareholder Returns

688136CN BiotechsCN Market
7D-9.2%-4.7%-1.9%
1Y-34.4%-35.5%-18.6%

Return vs Industry: 688136 matched the CN Biotechs industry which returned -35.1% over the past year.

Return vs Market: 688136 underperformed the CN Market which returned -17.7% over the past year.

Price Volatility

Is 688136's price volatile compared to industry and market?
688136 volatility
688136 Average Weekly Movement3.8%
Biotechs Industry Average Movement4.8%
Market Average Movement5.8%
10% most volatile stocks in CN Market9.3%
10% least volatile stocks in CN Market3.7%

Stable Share Price: 688136 is less volatile than 75% of CN stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: 688136's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19971,303n/ahttps://www.kexing.com

Kexing Biopharmaceutical Co., Ltd., a biopharmaceutical enterprise, engages in the research and development, production, and sale of recombinant protein therapeutics and microbiota agents. It focuses on pharmaceutical research in the therapeutic fields of antiviral, hematology, oncology, and immunology, as well as degenerative diseases. The company’s products include recombinant human interferon a1b, recombinant human erythropoietin, and recombinant human granulocyte colony-stimulating factor injections, as well as combined clostridium butyricum and bifidobacterium capsules (/powders); and KEHUANG CAPSUL, an optimal medicine that specializes in curing heat, toxin, swelling, and pain.

Shandong Kexing Bioproducts Co,.Ltd Fundamentals Summary

How do Shandong Kexing Bioproducts Co.Ltd's earnings and revenue compare to its market cap?
688136 fundamental statistics
Market CapCN¥3.99b
Earnings (TTM)CN¥38.61m
Revenue (TTM)CN¥1.32b

103.4x

P/E Ratio

3.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
688136 income statement (TTM)
RevenueCN¥1.32b
Cost of RevenueCN¥291.80m
Gross ProfitCN¥1.03b
Other ExpensesCN¥988.72m
EarningsCN¥38.61m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.19
Gross Margin77.88%
Net Profit Margin2.93%
Debt/Equity Ratio44.6%

How did 688136 perform over the long term?

See historical performance and comparison

Dividends

0.5%

Current Dividend Yield

63%

Payout Ratio